Life Sciences, Pharma & Healthcare

+ 18 other experts

The largest life sciences practice at a top-tier full-service firm in the Netherlands

.. with a practice that spans the entire spectrum of legal services relevant to the pharmaceutical and healthcare industry and to biotech companies.

We have strength and depth across this multifaceted sector, and advise on all relevant angles of legal life sciences work: ranging from M&A, financing transactions, IPOs (on Euronext Amsterdam, NASDAQ or other venues), corporate and governance, licensing transactions (often on a global scale), competition, regulatory and IP strategic advice through to litigation, compliance and investigations.

Our in-house capabilities give us a unique position from which to advise clients involved in life sciences matters which are by nature, often multidisciplinary. We are regularly retained for major transactions in the life sciences sector and our litigation department handles several of the largest healthcare and life sciences cases in the Netherlands, ranging from patent litigation to class actions pertaining to faulty medical devices and medicine.

Recent Matters

20 February 2025

Axcel acquires De Tandartsengroep from HC Partners through its portfolio company Oral Care to create Northern European dental group

Axcel-backed Oral Care, a Sweden-based dental care service provider in Sweden, Norway and the Netherlands, has signed an agreement to acquire Dutch dental care provider De Tandartsengroep (DTG). The acquisition will significantly expand the group’s presence in the Netherlands and marks another step in Oral Care’s aspirations in becoming a leading dental care group in Northern Europe.
16 December 2024

De Brauw advises underwriters on NewAmsterdam Pharma's USD 479 million public offering of shares and pre-funded warrants

De Brauw advised the underwriters on the upsized USD 479 million public offering of shares and pre-funded warrants by NASDAQ listed NewAmsterdam Pharma Company N.V.
9 December 2024

QIAGEN N.V. to issue USD 500 million net share settled convertible bonds

QIAGEN N.V. has launched an issuance of USD 500 million senior unsecured net share settled convertible bonds. This type of bond differs from "regular" convertible bonds in that they may only partly - for the amount "in the money" under the embedded warrant - be converted into ordinary shares of the company. In the event of an exercise of their conversion right, holders of the convertible bonds receive a cash amount equivalent to the par value of the convertible bonds, plus a number of shares such that the sum of the cash amount and value of shares delivered is equivalent to the value of the shares underlying the convertible bonds. The 7-year convertible bonds with a denomination of USD 200,000 each carry a conversion price that represents a premium of 44% above the reference price of the shares.
Landscape debrauw paper blackstone duo high res 3

We cover a broad spectrum of Life Sciences work for pharmaceutical companies, biotech firms and medical supply companies.

On behalf of our strong client base in the food and drink industry (Unilever, PepsiCo, Danone, JDE and P&G to name but a few), we have a leading role in developments relating to food claims and the actions taken by the European Food Safety Authority (EFSA).

We are the patent litigation firm of choice for many multinationals wishing to coordinate their patent strategy throughout Europe. Our Patent Law practice members combine their strong foundation in patent and procedural law with their extensive knowledge of the economics of, and the mechanisms, in this sector.

Learn More about our patents practice

A strong Dutch full service firm with the patent department also having a focus on Life Sciences... unique in combining legal and technical thinking when developing strategies and arguments. This team is unique in their extraordinary ability to learn the subject matter in a very short time, applying it in court and turn it into victory... They are a pleasure to work with both on a professional and a personal level.

Legal 500, 2021

Team

Bertrand ter Woort

Senior Associate

Bernard Spoor

Retired partner | Brauwerij supervisor